
# 1 Evaluating the effect of metabolic traits on oral and oropharyngeal

# 2 cancer risk using Mendelian randomization



19

**Abstract** 

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

A recent World Health Organization report states that at least 40% of all cancer cases may be preventable, with smoking, alcohol consumption and obesity identified as three of the most important modifiable lifestyle factors. Given the significant decline in smoking rates, particularly within developing countries, other potentially modifiable risk factors for head and neck cancer warrant investigation. Obesity and related metabolic disorders such as type 2 diabetes and hypertension have been associated with head and neck cancer risk in multiple observational studies. However, obesity has also been correlated with smoking, with bias, confounding or reverse causality possibly explaining these findings. To overcome the challenges of observational studies, we conducted two-sample Mendelian randomization (inverse variance weighted (IVW) method) using genetic variants which were robustly associated with obesity, T2D and hypertension in genome-wide association studies (GWAS). Outcome data was taken from the largest available GWAS of 6,034 oral and oropharyngeal cases, with 6,585 controls. We found limited evidence of a causal effect of genetically proxied body mass index (OR IVW = 0.89, 95%CI 0.72-1.09, p = 0.26 per 1 SD in BMI (4.81 kg/m2)) on oral and oropharyngeal cancer risk. Similarly, there was limited evidence for related traits including type 2 diabetes and hypertension. Smoking appears to act as a mediator in the relationship between obesity and head and neck cancer.

# Introduction

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

Head and neck squamous cell carcinoma (HNC), which includes cancers of the oral cavity and oropharynx is the 7<sup>th</sup> most common cancer, accounting for more than 660,000 new cases and 325,000 deaths annually worldwide (Johnson et al., 2020; Sung et al., 2021). Established risks include tobacco use, alcohol consumption (Hashibe et al., 2009) and human papillomavirus (HPV) infection, mainly associated with oropharyngeal cancer and thought to be sexually transmitted (Gillison, Chaturvedi, Anderson, & Fakhry, 2015). A recent World Health Organization (WHO) report states that at least 40% of all cancer cases may be preventable, with smoking, alcohol consumption and obesity identified as three of the most important modifiable lifestyle factors (World Health Organization (WHO), 2022). Smoking behaviour is declining, particularly in developing countries and it has been projected that obesity could even supersede smoking as the primary driver of cancer in the coming decades (World Health Organization (WHO), 2022). Despite changes in smoking rates, the incidence of HNC continues to rise and a changing aetiology has been proposed (Conway, 2018; Thomas, Penfold, Waylen, & Ness, 2018). Therefore, less established risks such as obesity and its related metabolic traits warrant investigation in HNC. However, obesity has been correlated with other HNC risk factors such as smoking (Carreras-Torres et al., 2018), alcohol (Alice R. Carter et al., 2019) and educational attainment (A. R. Carter et al., 2019), meaning independent effects are difficult to establish. Obesity is now considered to increase the risk of at least 13 different types of cancer including breast, colorectal, gastric and oesophageal (Centers for Disease Control and Prevention, 2021), but the effect on HNC risk remains unclear (World Health Organization

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

(WHO), 2022). Public health strategies have been unsuccessful in addressing the current obesity epidemic at the population level, which could result in more cancer cases in the years to come (Davey, 2004). Obesity and related metabolic traits such as type 2 diabetes (T2D), hypertension and dyslipidaemia have all been associated with head and neck cancer in multiple observational studies. In the largest pooled analysis, obesity defined by higher body mass index (BMI) was associated with a protective effect for HNC in current smokers (hazard ratio (HR)20.76, 95% confidence intervals (95%CI) 0.71-0.82, p2<0.0001, per 5½kg/m²) and conversely, a higher risk in never smokers (HR 1.15, 95%Cl 1.06-1.24 per  $5\mathbb{R} \log m^2$ , p < 0.001) (Gaudet et al., 2015). In the same study, a greater waist circumference (WC) (HR221.04, 95%CI 1.03−1.05 per 52cm, p2 < 0.001) and waist-to-hip ratio (WHR) (HR $\mathbb{P}1.07, 95\%$ Cl 1.05-1.09 per 0.1 unit, p < 0.001) were associated with increased HNC risk, which did not vary by smoking status (Gaudet et al., 2015). However, more recent cohort studies have failed to show a clear association between BMI and HNC (Cao et al., 2020; Diaz et al., 2021; Gribsholt et al., 2020; Jiang et al., 2021; Ward et al., 2017). A meta-analysis of observational studies investigating T2D with oral and oropharyngeal subsites, showed an increased risk ratio (RR) of 1.15, 95%CI 1.02-1.29, P heterogeneity = 0.277 (Gong, Wei, Yu, & Pan, 2015), a result which is consistent with more recent independent cohorts (Jiang et al., 2021; H.-B. Kim, Kim, Han, & Joo, 2021; S.-Y. Kim, Han, & Joo, 2019; Saarela et al., 2019). Hypertension (defined as a systolic blood pressure (SBP) > 130 mmHg or diastolic blood pressure (DBP) > 85 mmHg), has been correlated with head and neck cancer risk across multiple studies (Christakoudi et al., 2020; H.-B. Kim et al., 2021; S.-Y. Kim et al., 2019; Seo, Kim, Park, Han, & Joo, 2020; Stocks et al., 2012). Nonetheless, selection bias, confounding, or reverse causation may explain the findings from these studies.

Mendelian randomization (MR) is an analytical approach which attempts to overcome the challenges of conventional epidemiological studies. The method uses germline genetic single nucleotide polymorphisms (SNPs), which are randomly assorted during meiosis (and fixed at conception), to estimate the causal effects of exposures on disease outcomes (Davey Smith & Hemani, 2014; Sanderson et al., 2022; Smith & Ebrahim, 2003). Using MR, we recently found limited evidence for a role of circulating lipid traits in oral and oropharyngeal cancer risk (Gormley et al., 2021), however other metabolic traits remain untested in an MR framework. Here, we employ a two-sample MR approach, integrating summary-level genetic data from the largest available GWAS for metabolic traits, including obesity measures (BMI, WC, WHR), glycaemic traits (T2D, glycated haemoglobin (HbA<sub>1c</sub>), fasting glucose (FG), fasting insulin (FI)), and blood pressure (SBP, DBP) to evaluate their causal effect on oral and oropharyngeal cancer risk. Given the potential correlation of metabolic traits and established HNC risk factors, further evaluation of instrument-risk factor effects including smoking, alcohol, risk tolerance (as a proxy for sexual behaviour), and educational attainment was carried out using MR.

## Methods

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108


109

110

111

112

Two-sample MR was performed using published summary-level data from the largest available GWAS for each metabolic trait. MR makes three key assumptions, as described in **Figure 1** (Davey Smith & Hemani, 2014; Smith & Ebrahim, 2003).



**Figure 1.** Directed acyclic graph (DAG) depicting Mendelian randomization applied to this study

Genetic variants (G) act as proxies or instruments to investigate if an exposure (X), is associated with a trait e.g., body mass index or disease outcome (Y) e.g., oral/oropharyngeal cancer. Causal inference can be made between X and Y if the following conditions are upheld:

- (1) G is a valid instrument, reliably associated with X ('relevance');
- 121 (2) no measured (C) or unmeasured (U) confounding of the association between G and the Y
- 122 ('exchangeability');

123 (3) there is no independent association of G with Y, except through X ('exclusion restriction principle').

## **Exposure summary statistics for metabolic traits**

To instrument metabolic traits, we selected genetic variants associated ( $p < 5 \times 10^{-8}$ ) with traits of interest identified by previously conducted GWAS (**Supplementary file 1**). Clumping was performed to ensure single nucleotide polymorphisms (SNPs) in each instrument were independent (linkage disequilibrium  $R^2 < 0.001$ ). Following clumping, genetic instruments

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

were comprised of: 312 SNPs for BMI, from a GWAS meta-analysis of 806,834 individuals of European ancestry, including the Genetic Investigation of ANthropometric Traits (GIANT) consortium and UK Biobank (Pulit et al., 2019); and 209 SNPs for WHR extracted from the same GWAS in 697,734 individuals (Pulit et al., 2019). 45 SNPs for WC were taken from a GWAS meta-analysis describing 224,459 individuals of mainly European ancestry (Shungin et al., 2015); 275 SNPs for T2D from the DIAMANTE (DIAbetes Meta-ANalysis of Trans-Ethnic association studies) consortium of 228,499 cases and 1,178,783 controls (Vujkovic et al., 2020); 33 SNPs for FG and 18 SNPs for FI, obtained from a GWAS published by the MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits) Consortium (N = 151,188 and 105,056 individuals, respectively) (Lagou et al., 2021); 58 SNPs for HbA<sub>1c</sub>, taken from a meta-analyses of 159,940 individuals from 82 cohorts of European, African, East Asian, and South Asian ancestry (Wheeler et al., 2017); Finally, 105 and 78 SNPs for SBP and DBP, respectively, were extracted from a GWAS meta-analysis of over 1 million participants in UK Biobank and the International Consortium of Blood Pressure Genome Wide Association Studies (ICBP) (Evangelou et al., 2018) (Supplementary file 1).

#### Outcome summary statistics for oral and oropharyngeal cancer

We estimated the effects of metabolic traits on risk of oral and oropharyngeal cancer by extracting exposure SNPs (Supplementary file 1) from the largest available GWAS performed on 6,034 cases and 6,585 controls from 12 studies which were part of the Genetic Associations and Mechanisms in Oncology (GAME-ON) Network (Lesseur et al., 2016). Full details of the included studies, as well as the genotyping and imputation performed, have been described previously (Dudding et al., 2018; Lesseur et al., 2016). In

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

brief, the study population included participants from Europe (45.3%), North America (43.9%) and South America (10.8%). Cancer cases comprised the following the International Classification of Diseases (ICD) codes: oral cavity (C02.0-C02.9, C03.0-C03.9, C04.0-C04.9, C05.0-C06.9) oropharynx (C01.9, C02.4, C09.0-C10.9), hypopharynx (C13.0-C13.9), overlapping (C14 and combination of other sites) and 25 cases with unknown ICD code (other). A total of 954 individuals with cancers of hypopharynx, unknown code or overlapping cancers were excluded. Genomic DNA isolated from blood or buccal cells was genotyped at the Center for Inherited Disease Research (CIDR) using an Illumina OncoArray, custom designed for cancer studies by the OncoArray Consortium (Consortium, 2013). Principle components analysis was performed using approximately 10,000 common markers in low LD ( $r^2 < 0.004$ ), minor allele frequency (MAF) > 0.05 and 139 population outliers were removed. Given the differential association of potential risk factors at each subsite (i.e. smoking, alcohol and HPV infection)(Thomas et al., 2018), we performed stratified MR analyses for oral and oropharyngeal cancer to evaluate potential heterogeneity in effects. For this, we used GWAS summary data on a subset of 2,990 oral and 2,641 oropharyngeal cases and the 6,585 common controls in the GAME-ON GWAS (Lesseur et al., 2016). Statistical analysis Two-sample MR was conducted using the "TwoSampleMR" package in R (version 3.5.3), by integrating SNP associations for each metabolic trait (exposure, sample 1) with those for oral and oropharyngeal cancer in GAME-ON (outcome, sample 2). We only used genetic

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

variants reaching GWAS significance ( $p < 5 \times 10^{-8}$ ). The nearest gene was identified using SNPsnap and a distance of +/- 500 kb (Pers, Timshel, & Hirschhorn, 2014). Firstly, metabolic trait-associated SNPs were extracted from oral and oropharyngeal cancer summary statistics. Exposure and outcome summary statistics were harmonised using the "harmonise data" function of the TwoSampleMR package so that variant effect estimates corresponded to the same allele. Palindromic SNPs were identified and corrected using allele frequencies where possible (alleles were aligned when minor allele frequencies were < 0.3, or were otherwise excluded). For each SNP in each exposure, individual MR effectestimates were calculated using the Wald method (SNP-outcome beta/SNP-exposure beta) (Wald, 1940). Multiple SNPs were then combined into multi-allelic instruments using random-effects inverse-variance weighted (IVW) meta-analysis. IVW estimates may be vulnerable to bias if genetic instruments are invalid and are only unbiased in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced (Hemani, Bowden, & Smith, 2018). We therefore performed additional sensitivity analyses to evaluate the potential for unbalanced horizontal pleiotropy using weighted median (Bowden, Smith, Haycock, & Burgess, 2016), weighted mode (Hartwig, Smith, & Bowden, 2017) and MR-Egger (Bowden, Davey Smith, & Burgess, 2015) methods which are described in detail elsewhere (Lawlor DA, 2019). In short, the weighted median stipulates that at least 50% of the weight in the analysis stems from valid instruments. Weighted mode returns an unbiased estimate of the causal effect if the cluster with the largest weighted number of SNPs for the weighted model are all valid instruments. Instruments are weighted by the inverse variance of the SNP-outcome association (Hartwig et al., 2017).

Finally, MR-Egger provides reliable effect estimates even if variants are invalid and the Instrument Strength Independent of Direct Effect (InSIDE) assumption is violated (Bowden et al., 2015). The InSIDE assumption states that the association between genetic instrument and exposure should not be correlated with an independent path from instrument to the outcome. In the presence of unbalanced pleiotropy when the InSIDE assumption is violated, then the MR-Egger result may be biased (Lawlor DA, 2019). Gene variants must be valid instruments and where there was evidence of violation of the negligible measurement error (NOME) assumption (Bowden, Del Greco, et al., 2016), this was assessed using the I<sup>2</sup> statistic and MR-Egger was performed with simulation extrapolation (SIMEX) correction for bias adjustment (Bowden, Del Greco, et al., 2016). The variance of each trait explained by the genetic instrument  $(R^2)$  was estimated and used to perform power calculations (Brion, Shakhbazov, & Visscher, 2013). F-statistics were also generated. An F-statistic lower than 10 was interpreted as indicative of a weak instrument bias (Lawlor, Harbord, Sterne, Timpson, & Davey Smith, 2008). To further assess the robustness of MR estimates, we examined evidence of heterogeneity across individual SNPs using the Cochran Q-statistic, which indicates the presence of invalid instruments (e.g., due to horizontal pleiotropy), if Q is much larger than its degrees of freedom (No. of instrumental variables minus 1) (Bowden et al., 2018). MR-PRESSO (Mendelian Randomization Pleiotropy RESidual Sum and Outlier) was used to detect and correct for potential outliers (where Q-statistic p < 0.05) (Verbanck, Chen, Neale, & Do, 2018).

#### Instrument-risk factor effects

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

Where there was evidence for an effect of a metabolic trait on oral or oropharyngeal cancer risk in the primary MR analysis, we conducted further evaluation of the metabolic instruments onto established HNC risk factors using two-sample MR. The largest available GWAS were used for smoking initiation (a binary phenotype indicating whether an individual had ever smoked in their life versus never smokers) (n=121,232,091) and alcoholic drinks per week (defined as the average number of drinks per week aggregated across all types of alcohol, n=2941,280) from the GWAS and Sequencing Consortium of Alcohol and Nicotine use (GSCAN) study (Liu et al., 2019). Summary statistics were also obtained from a GWAS of general risk tolerance (n=1939,908), derived from a meta-analysis of UK Biobank (n=2431,126) binary question "Would you describe yourself as someone who takes risks?" and the 23andMe (n=2508,782) question "Overall, do you feel comfortable or uncomfortable taking risks?". The GWAS of risk tolerance was based on one's tendency or willingness to take risks, making them more likely to engage in risk-taking behaviours more generally (Karlsson Linner et al., 2019). A strong genetic correlation between sexual behaviours and risk tolerance has been shown previously (Gormley et al., 2022). Finally, given the known association between HNC and lower socioeconomic position, we used MR to examine educational attainment (defined by years of schooling) (J. Lee et al., 2018). Outcome beta estimates reflect the standard deviation of the phenotype.

## **Results**

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

F-statistics of genetic instruments for metabolic traits ranged from 33.3 – 133.6, indicating sufficient instrument strength for MR analyses (**Supplementary file 2 – table S1**). Genetic instruments were estimated to explain between 0.5% (FI) and 4% (BMI) of their respective

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

metabolic trait (Supplementary file 2 - table S1). Based on the results of prior observational studies we would expect to detect OR of >1.10 for a clinically meaningful effect of metabolic traits on oral and oropharyngeal cancer. Supplementary file 2 - figure **S1A-C** displays power estimates for MR analyses. In analyses where BMI was the exposure, we had 70% power to detect an association with an OR of 1.2 or more at an  $\alpha$  of 0.05 for combined oral and oropharyngeal cancer. Power was lower for other metabolic traits and reduced when stratifying analyses by subsite (Supplementary file 2 - figure S1B-C). Estimated effect of adiposity on oral and oropharyngeal cancer risk There was limited evidence of an effect of higher BMI or WHR on combined oral and oropharyngeal cancer (OR IVW = 0.89, 95%CI 0.72-1.09, p = 0.26, per 1 SD in BMI (4.81 $kg/m^2$ ) and OR IVW = 0.98, 95%CI 0.74–1.29, p = 0.88, per 1 SD in WHR (0.10 unit)) (**Table 1**, Figure 2, Supplementary file 2 - figure S2-S3). Results were consistent when analyses were stratified by subsite (Table 1). WC, another measure of adiposity did show a protective direction of effect (OR IVW = 0.73, 95%CI 0.52–1.02, p = 0.07, per 1 SD increase in WC (0.09) unit)), particularly in the oropharyngeal subsite (OR IVW = 0.66, 95%CI 0.43-1.01, p = 0.06, per 1 SD increase in WC (0.09 unit)) (Table 1, Figure 2, Supplementary file 2 - figure S4). Estimated effect of glycaemic traits on oral and oropharyngeal cancer risk There was limited evidence for an effect of genetically-proxied T2D on combined oral and oropharyngeal cancer (OR IVW = 0.92, 95%Cl 0.84-1.01, p = 0.09, per 1-log unit higher odds of T2D (Table 1, Figure 2, Supplementary file 2 - figure S5). Traits related to diabetes, including HbA<sub>1c</sub> resulted in a weak protective effect on combined oral and oropharyngeal cancer risk (OR IVW = 0.56, 95%CI 0.32-1.00, p = 0.05, per 1-log-unit % higher HbA<sub>1c</sub>), which

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

remained only in the oral subsite (OR IVW = 0.48, 95%CI 0.24-0.93, p = 0.03, per 1-log-unit % higher HbA<sub>1c</sub>) following stratification (Table 1, Figure 2, Supplementary file 2 – figure S6). Conversely, there was limited evidence of an effect for FG (OR IVW = 1.06, 95%CI 0.68-1.66, p = 0.79, per 1-log unit increase in mmol/L fasting glucose) (**Table 1, Figure 2**, **Supplementary file 2** – figure **S7**) or FI (OR IVW = 0.81, 95%CI 0.23-2.89, p = 0.75, per 1-log unit increase in mmol/L fasting insulin) on combined oral and oropharyngeal cancer risk (Table 1, Figure 2, Supplementary file 2 – figure S8) Estimated effect of increased blood pressure oral and oropharyngeal cancer risk Finally, there was limited evidence for an effect of SBP on risk of combined oral and oropharyngeal cancer (OR IVW = 1.00, 95%Cl 0.97-1.03, p = 0.89, per 1 unit mmHg increase in systolic blood pressure) (Table 1, Figure 2, Supplementary file 2 - figure S9), which did not change when stratified by subsite. However, there was some weak evidence for a protective effect of DBP on risk of combined oral and oropharyngeal cancer (OR IVW = 0.93, 95%CI 0.87-1.00, p = 0.05, per 1 unit mmHg increase in diastolic blood pressure) (**Table 1**, Figure 2, Supplementary file 2 – figure S10).

Table 1. Mendelian randomization results of genetically-proxied metabolic traits with risk of oral and oropharyngeal cancer in GAME-ON


291

					IVW		Weighted median		Weighted mode		MR-Egger	
			<u> </u>					ī		1		
Exposure	Outcome	Exposure/ Outcome source	Outcome N	Number of SNPs	OR (95%CI)	P	OR (95%CI)	Р	OR (95%CI)	P	OR (95%CI)	P
234	Oral and oropharyngeal cancer combined	25.00.52	6,034	272	0.89 (0.72, 1.09)	0.26	0.71 (0.50, 1.00)	0.05	, ,	0.07	, ,	0.11
	Oral cancer	Pulit et al.	2,990	272	0.89 (0.72, 1.09)	0.28	0.83 (0.55, 1.28)	0.03	0.63 (0.37, 1.04)	0.52	0.66 (0.40, 1.10) 0.75 (0.39, 1.41)	0.11
ВМ∣		GWAS/ GAME-ON	,									
	Oropharyngea  cancer		2,641	272	0.89 (0.68, 1.15)	0.36	0.75 (0.50, 1.13)	0.17	0.53 (0.27, 1.03)	0.06	0.56 (0.29, 1.07)	0.08
	Oral and oropharyngeal cancer combined		6,034	43	0.73 (0.52, 1.02)	0.07	0.64 (0.40, 1.05)	0.08	0.67 (0.36, 1.26)	0.22	0.43 (0.17, 1.08)	0.08
WC	Oral cancer	Shungin <i>et al.</i> GWAS/	2,990	43	0.82 (0.53, 1.26)	0.36	0.66 (0.36, 1.21)	0.18	0.67 (0.32, 1.39)	0.29	0.54 (0.17, 1.76)	0.31
	Oropharyngeal cancer	GA ME-ON	2,641	43	0.66 (0.43, 1.01)	0.06	0.56 (0.30, 1.05)	0.07	0.37 (0.17, 0.83)	0.02	0.30 (0.09, 0.98)	0.05
	Oral and oropharyngeal cancer combined		6,034	176	0.98 (0.74, 1.29)	0.88	0.98 (0.64, 1.49)	0.92	0.95 (0.45, 2.00)	0.89	1.80 (0.87, 3.71)	0.11
WHR	Oral cancer	Pulit <i>et al.</i> GWAS/	2,990	176	1.18 (0.84, 1.65)	0.35	1.00 (0.58, 1.73)	0.99	0.69 (0.29, 1.67)	0.41	2.49 (1.02, 6.12)	0.05
	Oropharyngeal cancer	GA ME-ON	2,641	176	0.83 (0.59, 1.14)	0.25	0.88 (0.51, 1.50)	0.63	0.93 (0.37, 2.30)	0.87	1.19 (0.50, 2.86)	0.70
	Oral and oropharyngeal cancer combined		6,034	254	0.92 (0.84, 1.01)	0.09	0.85 (0.74, 0.97)	0.02	0.84 (0.71, 1.01)	0.06	0.91 (0.77, 1.09)	0.31
	Oral cancer	Vujkovic <i>et al.</i> GWAS/	2,990	254	0.94 (0.84, 1.05)	0.27	0.84 (0.72, 0.99)	0.04	0.82 (0.66, 1.02)	0.08	0.88 (0.71, 1.08)	0.22
T2D	Oropharyngeal cancer	GA ME-ON	2,641	254	0.94 (0.84, 1.05)	0.27	0.89 (0.73, 1.10)	0.29	1.02 (0.80, 1.30)	0.88	1.00 (0.81, 1.24)	0.99
HbA <sub>1c</sub>	Oral and oropharyngeal cancer combined	Wheeler <i>et al.</i> GWAS/	6,034	37	0.56 (0.32, 1.00)	0.05	0.52 (0.23, 1.20)	0.12	0.54 (0.24, 1.21)	0.14	0.37 (0.13, 1.05)	0.07

		GA ME-ON										
	Oral cancer	(Lesseur et al., 2016)	2,990	37	0.48 (0.24, 0.93)	0.03	0.51 (0.18, 1.41)	0.19	0.44 (0.15, 1.29)	0.14	0.30 (0.09, 1.03)	0.06
	Oropharyngea  cancer		2,641	37	0.66 (0.31, 1.40)	0.28	0.49 (0.15, 1.57)	0.23	0.57 (0.18, 1.85)	0.35	0.43 (0.11, 1.68)	0.23
	Oral and oropharyngeal cancer combined	Lagou et al.	6,034	28	1.06 (0.68, 1.66)	0.79	1.20 (0.62, 2.30)	0.59	1.13 (0.60, 2.12)	0.71	1.11 (0.48, 2.56)	0.80
FG	Oral cancer	GWAS/ GAME-ON (Lesseur et al., 2016)	2,990	28	1.05 (0.58, 1.92)	0.87	1.15 (0.48, 2.72)	0.75	0.99 (0.44, 2.23)	0.99	1.25 (0.39, 4.01)	0.70
	Oropharyngeal cancer		2,641	28	1.39 (0.77, 2.51)	0.28	1.24 (0.51, 3.03)	0.63	1.36 (0.59, 3.18)	0.48	1.38 (0.45, 4.18)	0.58
FI	Oral and oropharyngeal cancer combined	Lagou <i>et al.</i> GWAS/ GA ME-ON	6,034	17	0.81 (0.23, 2.89)	0.75	0.75 (0.20, 2.87)	0.68	0.60 (0.03, 10.79)	0.74	0.11 (0.001, 22.47)	0.43
	Oral cancer		2,990	17	0.96 (0.22, 4.16)	0.96	0.46 (0.08, 2.47)	0.37	0.45 (0.01, 19.02)	0.68	0.21 (0.0004, 107.21	0.63
	Oropharyngea  cancer		2,641	17	0.68 (0.16, 2.87)	0.59	0.66 (0.12, 3.67)	0.63	0.48 (0.05, 4.99)	0.55	0.09 (0.0002, 40.04)	0.45
SBP	Oral and oropharyngeal cancer combined	Evangelou <i>et al.</i>	6,034	83	1.00 (0.97, 1.03)	0.89	0.99 (0.94, 1.03)	0.55	0.98 (0.88, 1.09)	0.66	1.06 (0.92, 1.23)	0.39
	Oral cancer	GWAS/ GAME-ON (Lesseur et al., 2016)	2,990	83	1.01 (0.96, 1.06)	0.74	0.99 (0.93, 1.04)	0.65	0.95 (0.84, 1.08)	0.48	1.09 (0.90, 1.33)	0.37
	Oropharyngeal cancer		2,641	83	0.99 (0.95, 1.03)	0.65	0.99 (0.94, 1.05)	0.77	1.00 (0.88, 1.13)	0.94	1.03 (0.87, 1.23)	0.71
DBP 292	Oral and oropharyngeal cancer combined	Evangelou et al. GWAS/	6,034	64	0.93 (0.87, 1.00)	0.05	0.94 (0.86, 1.04)	0.22	1.10 (0.88, 1.38)	0.42	0.99 (0.80, 1.24)	0.95
	Oral cancer		2,990	64	0.95 (0.87, 1.04)	0.26	0.96 (0.86, 1.07)	0.45	1.17 (0.88, 1.56)	0.28	0.97 (0.74, 1.27)	0.81
	Oropharyngea  cancer	GA ME-ON	2,641	64	0.92 (0.84, 1.00)	0.05	0.94 (0.84, 1.05)	0.29	1.10 (0.86, 1.41)	0.45	1.00 (0.75, 1.30)	0.93

Abbreviations: IVW, inverse variance weighted; OR, odds ratio; CI, confidence intervals; P, p-value; BMI, body mass index; WC, waist circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting glucose; FI, fasting insulin; HbA<sub>1c</sub>, glycated haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically predicted BMI (4.81 kg/m²), WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA<sub>1c</sub> (1-log-unit % higher glycated haemoglobin), SBP (1 unit mmHg increase) and DBP (1 unit mmHg increase).

# **Figure 2.** Mendelian randomization results of genetically-proxied metabolic disorders with risk of oral and oropharyngeal cancer including sensitivity analyses in GAME-ON



Abbreviations: IVW, inverse variance weighted; OR, odds ratio with 95% confidence intervals; BMI, body mass index; WC, waist circumference; WHR, waist-hip ratio; T2D, type 2 diabetes mellitus; FG, fasting glucose; FI, fasting insulin; HbA1c, glycated haemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure. OR are expressed per 1 standard deviation (SD) increase in genetically predicted BMI (4.81 kg/m2), WC (0.09 unit), WHR (0.10 unit), T2D (1-log unit higher odds of T2D), FG (1-log unit increase in mmol/L fasting glucose), FI (1-log unit increase in mmol/L fasting insulin), HbA1c (1-log-unit % higher glycated haemoglobin), SBP (1 unit mmHg increase).

#### Sensitivity analyses

We conducted MR Egger, weighted median, and weighted mode analyses in addition to IVW (**Table 1, Figure 2**). The results of these analyses generally followed the same pattern as the

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

IVW results reported above, however, there were a number of exceptions. The results for HbA1c were not robust to sensitivity testing (p > 0.05 across methods) (Table 1, Figure 2). In the analysis of T2D on combined oral and oropharyngeal cancer, the weighted median result provided evidence for a weak protective effect (OR weighted median 0.85, 95%CI 0.74–0.97, p = 0.02). This effect appeared mainly in the oral subsite (OR weighted median 0.84, 95%CI 0.72-0.99, p = 0.04). Furthermore, in the analysis of WC on oropharyngeal cancer risk, the weighted mode supported IVW result, providing evidence of a protective effect (OR weighted mode 0.37, 95%CI 0.17–0.83, p = 0.02) (**Table 1, Figure 2**). There was clear evidence of heterogeneity in the SNP effect estimates OR IVW and MR Egger regression for WHR (Q IVW = 213.04, p = 0.03; Q MR Egger = 209.24, p = 0.04), T2D (Q IVW = 328.24, p < 0.01; Q MR Egger = 328.21, p < 0.01), FI (Q IVW = 32.87, p < 0.01; Q MR Egger = 31.63, p < 0.01) and DBP (Q IVW = 95.82 p < 0.01; Q MR Egger = 95.22, p < 0.01) (Supplementary file 2 - table S2). MR-Egger intercepts were not strongly indicative of directional pleiotropy (Supplementary file 2 - table S3), but there were outliers present on visual inspection of scatter plots (Supplementary file 2 – figures S11-19). MR-PRESSO identified 19 outliers for BMI, 2 outliers for WC, 12 outliers for WHR, 23 outliers for T2D, 4 outliers for HbA<sub>1c</sub>, 1 outlier for FG, 3 outliers for FI, 5 outliers for SBP, 7 outliers for DBP (Supplementary file 2 – tables S4-5). When correcting for these outliers, this yielded effects consistent with the primary IVW analysis except for adiposity and T2D instruments, which demonstrated a protective effect on combined oral and oropharyngeal cancer risk when outliers were excluded: BMI (OR IVW = 0.77, 95%CI 0.62–0.94, p = 0.01, per 1 SD in BMI  $(4.81 \text{ kg/m}^2)$ ; WC (OR IVW = 0.65, 95%CI 0.47–0.89, p = 0.01, per 1 SD in WC (0.09 unit)), and T2D (OR IVW = 0.91, 0.84–0.99, p = 0.03, per 1-log unit higher odds of T2D)

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

(Supplementary file 2 - table S6). Where there was evidence of violation of the NOME assumption for WC, FI, SBP and DBP (i.e., I<sup>2</sup> statistic < 0.90) (Supplementary file 2 – table 57), MR-Egger was performed with SIMEX correction. SIMEX effects were consistent with the null, except for SBP where an increased risk effect on combined oral and oropharyngeal cancer was found (OR IVW = 1.15, 95%CI 1.05-1.26, p < 0.01, per 1 unit mmHg increase in diastolic blood pressure) (Supplementary file 2 – table S8). Evaluating instrument-risk factor effects Where there was some evidence for an effect of BMI, WC, WHR, T2D, HbA<sub>1</sub>, and DBP on oral and oropharyngeal cancer, we carried out further MR analysis to determine causal effects of these metabolic instruments on established risk HNC risk factors. Obesity-related measures showed a strong causal effect on the risk of smoking initiation: BMI (Beta IVW 0.21 (standard error (SE) 0.03), p < 0.001, per 1 SD increase in BMI (4.81 kg/m<sup>2</sup>)), WC (Beta IVW 0.21 (SE 0.05), p < 0.001, per 1 SD increase in WC (0.09 unit)) and WHR (Beta IVW 0.18 (SE 0.03), p < 0.001, per 1 SD increase in WHR (0.10 unit)) (Supplementary file 2 – table S9). There was weaker evidence for an effect of BMI, WC, and genetic liability to T2D on consumption of alcoholic drinks per week: BMI (Beta IVW -0.04 (SE 0.01), p < 0.01, per 1 SD increase in BMI  $(4.81 \text{ kg/m}^2)$ ), WC (Beta IVW -0.09 (SE 0.02), p < 0.001, per 1 SD increase in WC (0.09 unit)) and T2D (Beta IVW -0.02 (SE 0.01), p < 0.001, per 1-log unit higher odds of T2D). BMI (Beta IVW 0.04 (SE 0.01), p < 0.001, per 1 SD increase in BMI (4.81 kg/m<sup>2</sup>)) and WHR (Beta IVW 0.04 (SE 0.02), p = 0.02, per 1 SD increase in WHR (0.10 unit)) were also estimated to increase general risk tolerance. Similarly, increased BMI or WHR and genetic liability to T2D were estimated to increase educational attainment (years of schooling): BMI (Beta IVW -0.16 (SE 0.02), p < 0.001, per 1 SD increase in BMI (4.81 kg/m2)), WHR (Beta IVW

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

-0.11 (SE 0.02), p < 0.001, per 1 SD increase in WHR (0.10 unit)), and T2D (Beta IVW -0.02 (SE 0.01), p < 0.01, per 1-log unit higher odds of T2D). However, there was strong evidence of both heterogeneity (Supplementary file 2 - table S10) and genetic pleiotropy (Supplementary file 2 - table S11) across most instrument-risk factor effects. With the exception of alcohol drinks per week, the estimated instrument-risk factor effects remained unchanged following the removal of outlier SNPs detected by MR-PRESSO (Supplementary file 2 – table S12). Discussion In this MR study we found limited evidence to support a causal role of genetically-predicted metabolic traits in oral and oropharyngeal cancer, suggesting the risk may have been previously overestimated in observational studies. Where weak evidence for an effect was found (i.e., a protective effect of  $HbA_{1c}$ ), these results were not robust to sensitivity analysis, including outlier correction. There was also strong evidence for instrument-risk factor effects, suggesting smoking may be a mediator between obesity and HNC. There are several biological mechanisms linking metabolic traits and cancer, but these have not been well explored in HNC (Gatenby & Gillies, 2004; Grimberg, 2003; Tseng, Lin, Lin, & Weng, 2014). Dysregulated metabolism is likely linked to the probability a cancer develops and progresses, given that tumours must adapt to satisfy the bioenergetic and biosynthetic demands of chronic cell proliferation via metabolic reprogramming, enhancing or suppressing the activity of metabolic pathways relative to that in benign tissue (DeNicola &

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

Cantley, 2015). In the largest pooled analysis of 17 case-control studies, BMI was associated with a higher risk of overall HNC, but when stratified by subsite the effect was mainly in the larynx (HR 1.42, 95%Cl 1.19–1.70 per 52kg/m<sup>2</sup>, p < 0.001) (Gaudet et al., 2015). Laryngeal cancer was not included in our study given that GWAS summary data were not available for this subsite and future analysis of this region is therefore warranted. BMI effects on both the oral (HR 1.10, 95%CI 0.97–1.25, p = 0.14) and oropharyngeal cancer (HR 0.98, 95%CI 0.84-1.14, p = 0.77) subsites were consistent with the effects found in our study (oral cancer OR 0.92, 95%Cl 0.71–1.19, p = 0.53; oropharyngeal cancer OR 0.89, 0.68–1.15, p = 0.530.36) (Gaudet et al., 2015). Conversely, the same pooled analysis found an increased risk for both WC (HR 1.09, 95%Cl 1.03–1.16, p = 0.006) and WHR (HR 1.17, 95%Cl 1.02–1.34, p = 0.006) 0.02), mainly in the oral subsite which were not replicated in our MR analysis. Varying patterns of results for these anthropometric measures have been found when stratifying by smoking status within observational studies (Gaudet et al., 2015). The relationship between obesity and HNC is complex. There appears to be a positive association between low BMI (<18.52kg/m²) and HNC risk, and a protective effect of BMI on HNC risk in current smokers but conversely, a higher risk in never smokers (Gaudet et al., 2015). This suggests smoking is a confounder, both as an established risk factor for HNC and in its correlation with weight, with nicotine affecting metabolic energy expenditure, leading to reduced calorie absorption and appetite suppression (Williamson et al., 1991). Instrument-risk factor effect estimates from this study suggest smoking is also a mediator, through which metabolic traits such as BMI influence HNC risk. Despite metabolic syndrome (including hypertension, central obesity, elevated triglyceride, low HDL-C and insulin resistance) being strongly associated with common cancers such as

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

colorectal and breast (Esposito, Chiodini, Colao, Lenzi, & Giugliano, 2012), this does not appear to be the case in head and neck cancer. A recent prospective study of 474,929 participants from UK Biobank investigating the effect of metabolic syndrome suggested those with the condition had no increased HNC risk (HR 1.05, 95%CI 0.90–1.22, p = 0.560) (Jiang et al., 2021). No definitive causal effects were detected for individual components of metabolic syndrome components either, supporting our MR results. While another large meta-analysis found individuals with T2D have an elevated risk of oral cancer (Gong et al., 2015), other more recent studies have found this effect to be mostly in laryngeal subsite (HR 1.25, 95%CI 1.12-1.40) which again we could not investigate in this study (H.-B. Kim et al., 2021). Hypertension is the most consistently reported metabolic trait to have an observational association with HNC risk across the subsites (Christakoudi et al., 2020; H.-B. Kim et al., 2021; S.-Y. Kim et al., 2019; Seo et al., 2020; Stocks et al., 2012). We did not identify a clear effect of either SBP or DBP on oral or oropharyngeal cancer using MR, again suggesting the possibility of residual confounding in observational studies. MR was employed in this study in an attempt to overcome the drawbacks of conventional epidemiological studies. However, there are a number of limitations with using this approach and if MR assumptions are violated, this too can generate spurious conclusions. While there was no evidence of weak instrument bias (F statistics > 10), there was heterogeneity present in at least four of the instruments (WHR, T2D, FI and DBP). This is expected to some extent, given that we are instrumenting multiple biological pathways that contribute to complex metabolic phenotypes. The use of multiple related instruments for each metabolic trait may, however, provide some additional confidence in the overall findings. Given the low percentage of variation explained  $(R^2)$  for some instruments, as well

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

as the relatively small number of oral and oropharyngeal cancer cases, power to detect an effect may have been an issue in some of our analyses. As with observational studies, there may be issues of measurement error or misclassification in genetic epidemiology, given BMI is simply a function of mass and height and does not specifically measure adiposity. However, BMI has been shown to be an acceptable proxy when used in large samples sizes, correlating with both total body fat (Browning et al., 2011) and total abdominal adipose tissue (Ross, Léger, Morris, de Guise, & Guardo, 1992), which is thought to present a greater health risk than fat deposited elsewhere. Furthermore, we used a range of adiposity measures including WC and WHR, which may be better proxies of abdominal adiposity, compared to BMI (C. M. Lee, Huxley, Wildman, & Woodward, 2008). SNPs used to proxy these metabolic traits, particularly obesity-related measures BMI, WC and WHR were strongly associated with smoking. Given the heterogeneity of these complex metabolic traits, future work could further examine their pathway specific effects (Udler et al., 2018). Conclusion Overall, there was limited evidence for an effect of genetically-proxied metabolic traits on oral and oropharyngeal cancer risk. These findings suggest metabolic traits may not be effective modifiable risk factors to prioritise as part of future prevention strategies in head and neck cancer. The effect of metabolic traits on the risk of this disease may have been overestimated in previous observational studies, but these cannot be directly compared

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

given the differences in methodological approaches and the interpretation of estimates. Smoking appears to act as a mediator in the relationship between obesity and HNC. Although there is no clear evidence that changing body mass will reduce of increase the risk of HNC directly, dental and medical teams should be aware of the risk of smoking in those who are overweight and therefore the greater risk of cancer when providing smoking cessation and appropriate weight loss advice. References Bowden, J., Davey Smith, G., & Burgess, S. (2015): Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International Journal of Epidemiology, 44, 512-525. Bowden, J., Del Greco, M. F., Minelli, C., Smith, G. D., Sheehan, N. A., & Thompson, J. R. (2016): Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I-2 statistic. International Journal of Epidemiology, **45**, 1961-1974. Bowden, J., Smith, G. D., Haycock, P. C., & Burgess, S. (2016): Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic Epidemiology, 40, 304-314. Bowden, J., Spiller, W., Del Greco, F., Sheehan, N., Thompson, J., Minelli, C., & Smith, G. D. (2018): Improving the visualization, interpretation and analysis of two-sample

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

summary data Mendelian randomization via the Radial plot and Radial regression. International Journal of Epidemiology, 47, 1264-1278. Brion, M. J., Shakhbazov, K., & Visscher, P. M. (2013): Calculating statistical power in Mendelian randomization studies. International Journal of Epidemiology, 42, 1497-1501. Browning, L. M., Mugridge, O., Dixon, A. K., Aitken, S. W., Prentice, A. M., & Jebb, S. A. (2011): Measuring abdominal adipose tissue: comparison of simpler methods with MRI. Obesity facts, 4, 9-15. Cao, Z., Li, S., Xu, F., Yang, X., Wang, Y., Zheng, X., & Yang, H. (2020): Association of obesity status and metabolic syndrome with site-specific cancers: a population-based cohort study. British Journal of Cancer, 123, 1336-1344. Carreras-Torres, R., Johansson, M., Haycock, P. C., Relton, C. L., Davey Smith, G., Brennan, P., & Martin, R. M. (2018): Role of obesity in smoking behaviour: Mendelian randomisation study in UK Biobank. BMJ (Clinical research ed.), 361, k1767-k1767. Carter, A. R., Borges, M.-C., Benn, M., Tybjærg-Hansen, A., Davey Smith, G., Nordestgaard, B. G., & Lawlor, D. A. (2019): Combined Association of Body Mass Index and Alcohol Consumption With Biomarkers for Liver Injury and Incidence of Liver Disease: A Mendelian Randomization Study. JAMA Network Open, 2, e190305-e190305. Carter, A. R., Gill, D., Davies, N. M., Taylor, A. E., Tillmann, T., Vaucher, J., . . . Dehghan, A. (2019): Understanding the consequences of education inequality on cardiovascular disease: mendelian randomisation study. BMJ, 365, 11855.

499

500

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

Centers for Disease Control and Prevention. (2021). Obesity and Cancer [Internet] [cited 2022 Jun 18]. Retrieved from https://www.cdc.gov/cancer/obesity/index.htm#:~:text=Being%20overweight%20or %20having%20obesity,the%20United%20States%20each%20year. Christakoudi, S., Kakourou, A., Markozannes, G., Tzoulaki, I., Weiderpass, E., Brennan, P., . . . Tsilidis, K. K. (2020): Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 146, 2680-2693. Consortium, O. (2013): Consortium launches genotyping effort. Cancer Discov, 3, 1321-1322. Conway, D. I., Purkayastha, M., Chestnutt, I. G. (2018): The changing epidemiology of oral cancer: definitions, trends, and risk factors. British Dental Journal, 225, 867-873. Davey, R. C. (2004): The obesity epidemic: too much food for thought? British Journal of Sports Medicine, **38**, 360-363. Davey Smith, G., & Hemani, G. (2014): Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Human Molecular Genetics, 23, R89-98. DeNicola, G. M., & Cantley, L. C. (2015): Cancer's Fuel Choice: New Flavors for a Picky Eater. Mol Cell, 60, 514-523. Diaz, Y., Duarte-Salles, T., Recalde, M., Freisling, H., Davila-Batista, V., Leitzmann, M., & Romieu, I. (2021): Body mass index and waist circumference in relation to the risk of 26 types of cancer: a prospective cohort study of 3.5 million adults in Spain. BMC Medicine, 19, 10-10.

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

Dudding, T., Johansson, M., Thomas, S. J., Brennan, P., Martin, R. M., & Timpson, N. J. (2018): Assessing the causal association between 25-hydroxyvitamin D and the risk of oral and oropharyngeal cancer using Mendelian randomization. International Journal of Cancer, **143**, 1029-1036. Esposito, K., Chiodini, P., Colao, A., Lenzi, A., & Giugliano, D. (2012): Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care, 35, 2402-2411. Evangelou, E., Warren, H. R., Mosen-Ansorena, D., Mifsud, B., Pazoki, R., Gao, H., . . . the Million Veteran, P. (2018): Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nature Genetics, 50, 1412-1425. Gatenby, R. A., & Gillies, R. J. (2004): Why do cancers have high aerobic glycolysis? Nature Reviews Cancer, 4, 891-899. Gaudet, M. M., Kitahara, C. M., Newton, C. C., Bernstein, L., Reynolds, P., Weiderpass, E., . . . Gapstur, S. M. (2015): Anthropometry and head and neck cancer: a pooled analysis of cohort data. International Journal of Epidemiology, 44, 673-681. Gillison, M. L., Chaturvedi, A. K., Anderson, W. F., & Fakhry, C. (2015): Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. J Clin Oncol, 33, 3235-3242. Gong, Y., Wei, B., Yu, L., & Pan, W. (2015): Type 2 diabetes mellitus and risk of oral cancer and precancerous lesions: a meta-analysis of observational studies. Oral Oncology, **51**, 332-340.

540 Gormley, M., Dudding, T., Kachuri, L., Burrows, K., Chong, A. H. W., Martin, R. M., . . . 541 Richmond, R. C. (2022): Investigating the effect of sexual behaviour on 542 oropharyngeal cancer risk: a methodological assessment of Mendelian 543 randomization. BMC Medicine, 20, 40. 544 Gormley, M., Yarmolinsky, J., Dudding, T., Burrows, K., Martin, R. M., Thomas, S., . . . 545 Richmond, R. C. (2021): Using genetic variants to evaluate the causal effect of cholesterol lowering on head and neck cancer risk: A Mendelian randomization 546 547 study. PLOS Genetics, 17, e1009525. Gribsholt, S. B., Cronin-Fenton, D., Veres, K., Thomsen, R. W., Ording, A. G., Richelsen, B., & 548 549 Sorensen, H. T. (2020): Hospital-diagnosed overweight and obesity related to cancer 550 risk: a 40-year Danish cohort study. Journal of Internal Medicine, 287, 435-447. 551 Grimberg, A. (2003): Mechanisms by which IGF-I may promote cancer. Cancer biology & 552 therapy, 2, 630-635. 553 Hartwig, F. P., Smith, G. D., & Bowden, J. (2017): Robust inference in summary data 554 Mendelian randomization via the zero modal pleiotropy assumption. International 555 Journal of Epidemiology, 46, 1985-1998. 556 Hashibe, M., Brennan, P., Chuang, S. C., Boccia, S., Castellsague, X., Chen, C., . . . Boffetta, P. 557 (2009): Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck 558 Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology 559 Consortium. Cancer Epidemiology Biomarkers & Prevention, 18, 541-550.

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

579

Hemani, G., Bowden, J., & Smith, G. D. (2018): Evaluating the potential role of pleiotropy in Mendelian randomization studies. Human Molecular Genetics, 27, R195-R208. Jiang, H., Zhou, L., Jiang, K., Huang, X., He, Q., & Yuan, J. (2021): The effect of metabolic syndrome on head and neck cancer incidence risk: a population-based prospective cohort study. Cancer & metabolism, 9, 25-25. Johnson, D. E., Burtness, B., Leemans, C. R., Lui, V. W. Y., Bauman, J. E., & Grandis, J. R. (2020): Head and neck squamous cell carcinoma. Nature Reviews Disease Primers, 6, 92. Karlsson Linner, R., Biroli, P., Kong, E., Meddens, S. F. W., Wedow, R., Fontana, M. A., . . . Beauchamp, J. P. (2019): Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. Nature Genetics, 51, 245-257. Kim, H.-B., Kim, G.-J., Han, K.-d., & Joo, Y.-H. (2021): Changes in metabolic syndrome status and risk of laryngeal cancer: A nationwide cohort study. PLoS One, 16, e0252872e0252872. Kim, S.-Y., Han, K.-d., & Joo, Y.-H. (2019): Metabolic Syndrome and Incidence of Laryngeal Cancer: A Nationwide Cohort Study. Scientific Reports, 9, 667. Lagou, V., Mägi, R., Hottenga, J.-J., Grallert, H., Perry, J. R. B., Bouatia-Naji, N., . . . Insulinrelated traits, C. (2021): Sex-dimorphic genetic effects and novel loci for fasting glucose and insulin variability. Nature Communications, 12, 24.

580 Lawlor, D. A., Harbord, R. M., Sterne, J. A., Timpson, N., & Davey Smith, G. (2008): 581 Mendelian randomization: using genes as instruments for making causal inferences 582 in epidemiology. Statistics in Medicine, 27, 1133-1163. 583 Lawlor DA, W. K., Borges MC, Palmer T, Hartwig FP, Hemani G, Bowden JA. . (2019): A 584 Mendelian Randomization dictionary: Useful definitions and descriptions for 585 undertaking, understanding and interpreting Mendelian Randomization studies. 586 Lee, C. M., Huxley, R. R., Wildman, R. P., & Woodward, M. (2008): Indices of abdominal 587 obesity are better discriminators of cardiovascular risk factors than BMI: a meta-588 analysis. J Clin Epidemiol, 61, 646-653. 589 Lee, J., Wedow, R., Okbay, A., Kong, E., Maghzian, O., Zacher, M., . . . Social Science Genetic 590 Association, C. (2018): Gene discovery and polygenic prediction from a genome-wide 591 association study of educational attainment in 1.1 million individuals. Nature 592 Genetics, **50**, 1112-1121. 593 Lesseur, C., Diergaarde, B., Olshan, A. F., Wunsch, V., Ness, A. R., Liu, G., . . . Brennan, P. 594 (2016): Genome-wide association analyses identify new susceptibility loci for oral 595 cavity and pharyngeal cancer. Nature Genetics, 48, 1544-1550. 596 Liu, M. Z., Jiang, Y., Wedow, R., Li, Y., Brazel, D. M., Chen, F., . . . Psychiat, H. A. I. (2019): 597 Association studies of up to 1.2 million individuals yield new insights into the genetic 598 etiology of tobacco and alcohol use. Nature Genetics, 51, 237. 599 Pers, T. H., Timshel, P., & Hirschhorn, J. N. (2014): SNPsnap: a Web-based tool for 600 identification and annotation of matched SNPs. Bioinformatics, 31, 418-420.

601 Pulit, S. L., Stoneman, C., Morris, A. P., Wood, A. R., Glastonbury, C. A., Tyrrell, J., . . . 602 Lindgren, C. M. (2019): Meta-analysis of genome-wide association studies for body 603 fat distribution in 694 649 individuals of European ancestry. Human Molecular 604 Genetics, 28, 166-174. 605 Ross, R., Léger, L., Morris, D., de Guise, J., & Guardo, R. (1992): Quantification of adipose 606 tissue by MRI: relationship with anthropometric variables. J Appl Physiol (1985), 72, 607 787-795. 608 Saarela, K., Tuomilehto, J., Sund, R., Keskimaki, I., Hartikainen, S., & Pukkala, E. (2019): 609 Cancer incidence among Finnish people with type 2 diabetes during 1989-2014. 610 European Journal of Epidemiology, 34, 259-265. 611 Sanderson, E., Glymour, M. M., Holmes, M. V., Kang, H., Morrison, J., Munafò, M. R., . . . 612 Davey Smith, G. (2022): Mendelian randomization. Nature Reviews Methods Primers, 613 **2**, 6. 614 Seo, J.-H., Kim, Y.-D., Park, C.-S., Han, K.-d., & Joo, Y.-H. (2020): Hypertension is associated 615 with oral, laryngeal, and esophageal cancer: a nationwide population-based study. 616 Scientific Reports, 10, 10291. 617 Shungin, D., Winkler, T. W., Croteau-Chonka, D. C., Ferreira, T., Locke, A. E., Mägi, R., . . . 618 Mohlke, K. L. (2015): New genetic loci link adipose and insulin biology to body fat 619 distribution. Nature, 518, 187-196.

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

Smith, G. D., & Ebrahim, S. (2003): 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? International Journal of Epidemiology, **32**, 1-22. Stocks, T., Van Hemelrijck, M., Manjer, J., Bjorge, T., Ulmer, H., Hallmans, G., . . . Stattin, P. (2012): Blood pressure and risk of cancer incidence and mortality in the Metabolic Syndrome and Cancer Project. Hypertension (Dallas, Tex.: 1979), 59, 802-810. Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021): Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. Thomas, S. J., Penfold, C. M., Waylen, A., & Ness, A. R. (2018): The changing aetiology of head and neck squamous cell cancer: A tale of three cancers? Clinical Otolaryngology, 43, 999-1003. Tseng, K. S., Lin, C., Lin, Y. S., & Weng, S. F. (2014): Risk of head and neck cancer in patients with diabetes mellitus: a retrospective cohort study in Taiwan. JAMA Otolaryngol Head Neck Surg, 140, 746-753. Udler, M. S., Kim, J., von Grotthuss, M., Bonàs-Guarch, S., Cole, J. B., Chiou, J., . . . Florez, J. C. (2018): Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis. PLoS Med, 15, e1002654.

640 Verbanck, M., Chen, C. Y., Neale, B., & Do, R. (2018): Publisher Correction: Detection of 641 widespread horizontal pleiotropy in causal relationships inferred from Mendelian 642 randomization between complex traits and diseases. Nature Genetics, 50, 1196. 643 Vujkovic, M., Keaton, J. M., Lynch, J. A., Miller, D. R., Zhou, J., Tcheandjieu, C., . . . Program, 644 V. A. M. V. (2020): Discovery of 318 new risk loci for type 2 diabetes and related 645 vascular outcomes among 1.4 million participants in a multi-ancestry meta-analysis. 646 Nature Genetics, 52, 680-691. 647 Wald, A. (1940): The Fitting of Straight Lines if Both Variables are Subject to Error. The 648 Annals of Mathematical Statistics, 11, 284-300, 217. 649 Ward, H. A., Wark, P. A., Muller, D. C., Steffen, A., Johansson, M., Norat, T., . . . Riboli, E. 650 (2017): Measured Adiposity in Relation to Head and Neck Cancer Risk in the 651 European Prospective Investigation into Cancer and Nutrition. Cancer epidemiology, 652 biomarkers & prevention : a publication of the American Association for Cancer 653 Research, cosponsored by the American Society of Preventive Oncology, 26, 895-904. 654 Wheeler, E., Leong, A., Liu, C. T., Hivert, M. F., Strawbridge, R. J., Podmore, C., . . . Meigs, J. 655 B. (2017): Impact of common genetic determinants of Hemoglobin A1c on type 2 656 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-657 wide meta-analysis. PLoS Med, 14, e1002383. 658 Williamson, D. F., Madans, J., Anda, R. F., Kleinman, J. C., Giovino, G. A., & Byers, T. (1991): 659 Smoking Cessation and Severity of Weight Gain in a National Cohort. New England 660 Journal of Medicine, **324**, 739-745.

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

Wootton, R. E., Richmond, R. C., Stuijfzand, B. G., Lawn, R. B., Sallis, H. M., Taylor, G. M. J., . . . Munafo, M. R. (2019): Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: a Mendelian randomisation study. Psychol Med, 1-9. World Health Organization (WHO). (2022). WHO European Regional Obesity Report 2022. [Internet] [cited 2022 Jun 06]. Ethics approval and consent to participate All studies included as part of the GAME-ON network obtained approval and consent from their respective institutions. Consent for publication Not applicable. Availability of data and materials Summary-level analysis was conducted using publicly available GWAS data as cited. Full summary statistics for the GAME-ON outcome data GWAS can be accessed via dbGAP (OncoArray: Oral and Pharynx Cancer; study accession number: phs001202.v1.p1, August 2017) at: https://www.ncbi.nlm.nih.gov/projects/gap/cgibin/study.cgi?study id=phs001202.v1.p1) (Lesseur et al., 2016). This data is also available via the IEU OpenGWAS project (https://gwas.mrcieu.ac.uk/).

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

701

702

703

704

705

All exposure data used in this study is publicly available from the relevant studies as described below. Data for BMI, WC and WHR GWAS was downloaded from the Genetic Investigation of ANthropometric Traits (GIANT) consortium https://portals.broadinstitute.org/collaboration/giant/index.php/GIANT consortium data f iles (Pulit et al., 2019; Shungin et al., 2015) and UK Biobank (http://www.ukbiobank.ac.uk). T2D data was downloaded from the DIAMANTE (DIAbetes Meta-ANalysis of Trans-Ethnic association studies) consortium from: https://kp4cd.org/node/169 (Vujkovic et al., 2020). Data for FG, FI and HbA<sub>1c</sub>, were obtained from GWAS published by the MAGIC (Meta-Analyses of Glucose and Insulin-Related Traits) Consortium, available for download from: https://magicinvestigators.org/downloads/ (Lagou et al., 2021). Finally, data for SBP and DBP were extracted from a GWAS meta-analysis of participants in UK Biobank http://www.ukbiobank.ac.uk) and the International Consortium of Blood Pressure Genome Wide Association Studies (ICBP), available via dbGAP (International Consortium for Blood Pressure (ICBP), study accession number: phs000585.v2.p1, October 2016) at https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study\_id=phs000585.v2.p1 (Evangelou et al., 2018). Instrument-risk factor analysis outcome summary-level data were derived from the GWAS & Sequencing Consortium of Alcohol and Nicotine use (GSCAN) and UK Biobank and UK Biobank (http://www.ukbiobank.ac.uk) for alcoholic drinks per week https://conservancy.umn.edu/handle/11299/201564 (Liu et al., 2019) and the comprehensive smoking index (Wootton et al., 2019). Data for risk tolerance and educational attainment were taken from Social Science Genetic Association Consortium (SSGAC) data available from http://www.thessgac.org/data (Karlsson Linner et al., 2019; J.

707

708

709

710

711

712

713

714

715

716

717

718

719

720

721

722

723

724

725

726

727

728

729

Lee et al., 2018). MR analyses were conducted using the "TwoSampleMR" package in R (version 3.5.3). A copy of the code and all data files used in this study are available at GitHub (https://github.com/MGormley12/metabolic trait hnc mr.git). **Competing interests** The authors declare that they have no competing interests **Funding** M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship. This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC research fellow at the University of Bristol. J.T. is supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, Global Challenges Research Fund (GCRF), the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). A.R.N. was supported by the National Institute for Health Research (NIHR) Bristol Biomedical Research Centre which is funded by the National Institute for Health Research (NIHR) and is a partnership between University Hospitals Bristol NHS Foundation Trust and the University of Bristol. Department of Health and Social Care disclaimer: The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. This publication presents data from the Head and Neck 5000 which contributes to international VOYAGER and HEADSpAcE head and neck cancer consortia. The

731

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

Head and Neck 5000 study was a component of independent research funded by the National Institute for Health Research (NIHR) under its Programme Grants for Applied Research scheme (RP-PG-0707-10034). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Core funding was also provided through awards from Above and Beyond, University Hospitals Bristol and Weston Research Capability Funding and the NIHR Senior Investigator award to A.R.N. Human papillomavirus (HPV) serology was supported by a Cancer Research UK Programme Grant, the Integrative Cancer Epidemiology Programme (C18281/A20919). The VOYAGER study was supported in part by the US National Institute of Dental and Craniofacial Research (NIDCR; R01 DE025712). The genotyping of the HNC cases and controls was performed at the Center for Inherited Disease Research (CIDR) and funded by the US National Institute of Dental and Craniofacial Research (NIDCR; 1X01HG007780-0). E.E.V, C.B. and D.L. are supported by Diabetes UK (17/0005587). E.E.V, and C.B. are supported by the World Cancer Research Fund (WCRF UK), as part of the World Cancer Research Fund International grant programme (IIG 2019 2009). M.G., T.D., G.D.S, E.E.V., R.C.R, and C.B. are part of the Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research Council (MC UU 00011/1, MC UU 00011/5, MC UU 00011/6, MC UU 00011/7).